Hsa_circ_0065149 mediates the ceRNA network pathway: Research on the mechanism regulating myasthenia gravis.
CircRNAs have been linked to the pathogenesis and progression of myasthenia gravis (MG), but research on this association remains limited. This study aims to provide a new perspective for understanding the molecular pathogenesis of MG. We obtained RNA-seq data from patients with acetylcholine recept…
Anti-acetylcholine receptor antibody overshoot following efgartigimod in myasthenia gravis: Two case reports with literature review.
FcRn antagonists have reshaped generalized myasthenia gravis (MG) treatment by enhancing IgG catabolism, complementing traditional antibody-depleting therapy (ADT). However, disrupting IgG homeostasis may paradoxically cause antibody overshoot, potentially worsening MG symptoms. The risk factors and…
Comprehensive review on myasthenia gravis: patho-physiology, diagnosis, management strategies.
Myasthenia gravis (MG) is a heterogeneous autoimmune neuromuscular disorder with distinct serological subtypes, including antibodies against acetylcholine receptors (AChRs), MuSK, and LRP4. Despite increasing recognition of these subtypes, clinical practice still lacks a standardized, subt…
Breakthrough serogroup Y meningococcal disease in a vaccinated patient with myasthenia gravis receiving ravulizumab: a case report.
We report a case of fulminant invasive meningococcal disease caused by Neisseria meningitidis serogroup Y in a young, immunocompromised adult with myasthenia gravis receiving long-term immunosuppressive therapy including ravulizumab, despite prior meningococcal vaccination. Serogroup Y is increasing…
Non-Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis.
Rozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six-week cyclic regimen may be associated with a "wearing-off" effect and disease fluctuations. We evaluated th…
Real-world implications of efgartigimod in managing refractory myasthenia gravis.
Refractory myasthenia gravis (RMG) affects 10-20% of patients with generalized MG (gMG) and is associated with persistent disability, recurrent myasthenic crises, and elevated healthcare costs despite multiple lines of immunosuppressive therapy. Efgartigimod (EFG), an engineered IgG1 Fc fragment tha…
Celiac plexus radiosurgery for retroperitoneal pain in advanced cancer: a pre-specified secondary analysis of health-related quality of life in a phase II single-arm trial.
Retroperitoneal pain syndrome seen in pancreatic cancer is a major clinical challenge. Celiac plexus radiosurgery, a new palliative technique for retroperitoneal pain syndrome, decreased pain levels in a phase II study. Here Health-Related Quality of Life (HRQOL) outcomes are reported. Evaluable pat…
Coexistence of Parkinson's Disease and Myasthenia Gravis with Symptom Exacerbation Induced by Biperiden: A Case Report.
Advanced-stage Parkinson's disease (PD) and myasthenia gravis (MG) share overlapping clinical features, including dysphagia, dysarthria, fatigue, and fluctuating symptoms. When PD precedes MG, these manifestations may be misinterpreted as a progression of PD, potentially leading to an underdiagnosis…